The International Liver Cancer Association warmly thanks all Partners and Sponsors for their unrestricted support to the 2012 Annual Conference and their commitment to help advance liver cancer science.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
Sirtex Medical is an Australian publically listed company operating globally with offices in the US, Europe and Asia Pacific. Sirtex primary objective is to research and develop effective treatments for liver cancer using novel small particle technology. The lead product of Sirtex Medical, SIR-Spheres® microspheres, is a form of targeted internal radiotherapy which enables high doses of absorbed radiation to treat extensive unresectable liver tumours whilst conserving normal liver parenchyma. We are supporting an extensive and ongoing programme of prospective clinical trials with SIR-Spheres® microspheres in liver cancer including collaborative group and investigator-initiated studies as well as those run directly by the company.
Biocompatibles, with its heritage of leadership and innovation in interventional oncology, is now a BTG International group company. We are investing in product development and clinical trials to deliver on a shared vision of excellence in interventional medicine. For further information about BTG please visit our website at www.btgplc.com
ILCA 2012 is supported by a grant from Bristol-Myers Squibb.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis.
Since 2002, we have delivered 13 key new products to patients with serious diseases. Four of these medicines are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive pipelines in the industry.
What sets us apart? As a BioPharma leader, we believe it’s our commitment to patients with serious diseases and our focus on finding innovative medicines to combat those diseases.
As we make a difference in the lives of patients, we say, “Together we can prevail.”
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapies for cancer. The Company’s lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib.
Supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
For more than four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to develop a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care. To learn more about Lilly Oncology’s commitment to cancer, please visit www.LillyOncology.com.
Nordion, headquartered in Ottawa, Canada is a global leader in providing products and services for medical imaging, radiotherapeutics and sterilization technologies. The company’s TheraSphere® product is a powerful, well-tolerated Y-90 glass microsphere therapy for transarterial radioembolization (TARE) in hepatic neoplasia including hepatocellular carcinoma (HCC), providing demonstrated patient benefits and rapid administration set-up, leading to safe and quicker infusion. TheraSphere is offered at more than 100 sites world-wide.
Novartis Oncology delivers a broad range of innovative therapies aimed at improving and extending the lives of patients. These include Glivec® (imatinib), Tasigna® (nilotinib), Exjade® (deferasirox), Zometa® (zoledronic acid), Sandostatin® LAR® (octreotide/IM injection) and Femara® (letrozole). Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.
Varian Medical Systems, Inc. of Palo Alto, California, is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian Medical Systems employs approximately 5,700 people.